NASDAQ:FLDM - Fluidigm Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.22 -0.07 (-0.68 %)
(As of 02/15/2019 03:54 PM ET)
Previous Close$10.29
Today's Range$10.16 - $10.49
52-Week Range$4.65 - $10.41
Volume38,814 shs
Average Volume882,408 shs
Market Capitalization$401.85 million
P/E Ratio-12.84
Dividend YieldN/A
Beta2.29
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$112.96 million
Book Value$0.80 per share

Profitability

Net Income$-59,010,000.00

Miscellaneous

Employees505
Market Cap$401.85 million
OptionableOptionable

Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) posted its quarterly earnings results on Thursday, February, 7th. The medical research company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.07. The medical research company earned $32.33 million during the quarter, compared to analysts' expectations of $30.55 million. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 90.07%. View Fluidigm's Earnings History.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Fluidigm.

What is the consensus analysts' recommendation for Fluidigm?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.

Has Fluidigm been receiving favorable news coverage?

Headlines about FLDM stock have trended somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Fluidigm earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Fluidigm?

Fluidigm saw a increase in short interest in January. As of January 15th, there was short interest totalling 6,553,536 shares, an increase of 59.3% from the December 31st total of 4,114,687 shares. Based on an average daily trading volume, of 1,122,272 shares, the short-interest ratio is presently 5.8 days. Approximately 13.6% of the company's shares are sold short. View Fluidigm's Current Options Chain.

Who are some of Fluidigm's key competitors?

Who are Fluidigm's key executives?

Fluidigm's management team includes the folowing people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)
  • Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Steven C. McPhail, Chief Commercial Officer (Age 65)
  • Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60)

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Levin Capital Strategies L.P. (24.33%), BlackRock Inc. (5.44%), Pura Vida Investments LLC (1.73%), Acadian Asset Management LLC (1.37%), Two Sigma Investments LP (1.24%) and Bank of New York Mellon Corp (1.17%). Company insiders that own Fluidigm stock include Evan/ Fa Jones, Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Institutional Ownership Trends for Fluidigm.

Which major investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Connor Clark & Lunn Investment Management Ltd., D. E. Shaw & Co. Inc. and Northern Trust Corp. View Insider Buying and Selling for Fluidigm.

Which major investors are buying Fluidigm stock?

FLDM stock was acquired by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Two Sigma Investments LP, Two Sigma Advisers LP, BlackRock Inc., Royce & Associates LP, Squarepoint Ops LLC, Acadian Asset Management LLC and Cookson Peirce & Co. Inc.. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Insider Buying and Selling for Fluidigm.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $10.24.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $402.64 million and generates $112.96 million in revenue each year. The medical research company earns $-59,010,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Fluidigm employs 505 workers across the globe.

What is Fluidigm's official website?

The official website for Fluidigm is http://www.fluidigm.com.

How can I contact Fluidigm?

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000.


MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  432 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  696
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel